\-\ Texto\\:\\ \ \(0\)\
\-\ hiv\\ positive\ \(0\)\
\-\ antibiotic\\ therapy\ \(44\)\
\-\ \\â\\€\\¢\\ ct\\-\\ vague\\ low\\ density\\ lesions\\,\\ without\\ mass\\ effect\\.\ \(0\)\
\-\ \\â\\€\\¢\\ mri\\-\\ multiple\\ lesions\\,\\ hyperintense\\ on\\ non\\-contrast\\ t1\\ scans\ \(0\)\
\-\ \\â\\€\\¢\\ diffuse\\ \\ mild\\ enhancement\\ following\\ contrast\\ gd\\+\\ administration\ \(0\)\
\-\ toxoplasmosis\ \(14\)\
\-\ \\â\\€\\¢\\ metastatic\\ disease\ \(13\)\
\-\ \\â\\€\\¢\\ multicentric\\ glioma\ \(0\)\
\-\ \\â\\€\\¢\\ primary\\ cns\\ lymphoma\ \(0\)\
\-\ \\â\\€\\¢\\ toxoplasmosis\ \(0\)\
\-\ 29\\ year\\ old\\ mexican\\ man\\ with\\ seizures\\.\ \(0\)\
\-\ hiv\\ positive\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.19587679394948598\ \(0\)\
\-\ toxoplasmosis\\:\\ 0\\.1958326397782605\ \(0\)\
\-\ hiv\\:\\ 0\\.1692136064307421\ \(0\)\
\-\ gd\\+\\:\\ 0\\.1574199718565446\ \(0\)\
\-\ mexican\\:\\ 0\\.12868000913450708\ \(0\)\
\-\ multicentric\\:\\ 0\\.12028708718369038\ \(0\)\
\-\ mri\\-\\:\\ 0\\.10906193255114799\ \(0\)\
\-\ ct\\-\\:\\ 0\\.10142900371495264\ \(0\)\
\-\ positive\\:\\ 0\\.09903162822443273\ \(0\)\
\-\ vague\\:\\ 0\\.08207161997839985\ \(0\)\
\-\ lesions\\:\\ 0\\.08169858951228384\ \(0\)\
\-\ 29\\:\\ 0\\.07962159995137333\ \(0\)\
\-\ antibiotic\\:\\ 0\\.07808691370493182\ \(0\)\
\-\ cns\\:\\ 0\\.07808691370493182\ \(0\)\
\-\ non\\-contrast\\:\\ 0\\.07448442008616296\ \(0\)\
\-\ scans\\:\\ 0\\.07105779494669678\ \(0\)\
\-\ glioma\\:\\ 0\\.06879774631618912\ \(0\)\
\-\ seizures\\:\\ 0\\.06560455120471138\ \(0\)\
\-\ hyperintense\\:\\ 0\\.06335107615898518\ \(0\)\
\-\ administration\\:\\ 0\\.06335107615898518\ \(0\)\
\-\ effect\\:\\ 0\\.05402782594766509\ \(0\)\
\-\ density\\:\\ 0\\.050207702801070696\ \(0\)\
\-\ t1\\:\\ 0\\.04836599171829006\ \(0\)\
\-\ diffuse\\:\\ 0\\.04619656107813062\ \(0\)\
\-\ primary\\:\\ 0\\.045203290408851717\ \(0\)\
\-\ lymphoma\\:\\ 0\\.04361068989981224\ \(0\)\
\-\ following\\:\\ 0\\.04330853137323479\ \(0\)\
\-\ low\\:\\ 0\\.042431572372614274\ \(0\)\
\-\ enhancement\\:\\ 0\\.04090158510933992\ \(0\)\
\-\ therapy\\:\\ 0\\.04079715707572523\ \(0\)\
\-\ mild\\:\\ 0\\.04018309739162745\ \(0\)\
\-\ metastatic\\:\\ 0\\.038412667921715896\ \(0\)\
\-\ man\\:\\ 0\\.03608806862660713\ \(0\)\
\-\ without\\:\\ 0\\.03592880654211\ \(0\)\
\-\ contrast\\:\\ 0\\.034156708692998305\ \(0\)\
\-\ multiple\\:\\ 0\\.032139392919272654\ \(0\)\
\-\ disease\\:\\ 0\\.024941741807423288\ \(0\)\
\-\ mass\\:\\ 0\\.021222517981206508\ \(0\)\
\-\ year\\:\\ 0\\.017073308379873475\ \(0\)\
\-\ old\\:\\ 0\\.015623832086825974\ \(0\)\
\-\ on\\:\\ 0\\.012926625220811215\ \(0\)\
\-\ \\,\\:\\ 0\\.009668216625617405\ \(0\)\
\-\ with\\:\\ 0\\.0020893602873194596\ \(0\)\
\-\ \\.\\:\\ 0\\.001267840574905224\ \(0\)\
